

ForPatients

by Roche

Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Advanced Solid Tumors Esophageal Cancer Hepatocellular Carcinoma (HCC) Non-Small
Cell Lung Cancer (NSCLC) Triple Negative Breast Cancer Gastric Cancer Metastatic Solid
Tumors Clear Cell Renal Cell Carcinoma Melanoma Cervical Cancer Urothelial Carcinoma

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Trial Status
Recruiting

Trial Runs In
7 Countries

Trial Identifier
NCT05581004 2021-006708-34
GO43860

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT05581004 2021-006708-34 GO43860
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
